Repligen Corp (FRA:RGN)
€ 135.6 +6.8 (+5.28%) Market Cap: 7.76 Bil Enterprise Value: 7.66 Bil PE Ratio: 228.84 PB Ratio: 4.46 GF Score: 88/100

Repligen Corp at Leerink Global Healthcare Conference Transcript

Mar 10, 2026 / 03:20 PM GMT
Release Date Price: €108.65 (+7.84%)


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

RGEN.OQ - Repligen Corp
Repligen Corp at Leerink Global Healthcare Conference
Mar 10, 2026 / 03:20PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Great. .

Welcome everyone. I'm Puni Sada. I cover life science, tools and diagnostics, here at Lyric, and it's my pleasure to be hosting the Relision team, CFO Jason Garland, and also head of Investor relations, Jacob Johnson joining us. Great to have you guys here in Miami. Good morning for having us, Peet. Yeah, okay, excellent. So maybe, Always exciting to look, talk about repli and number of things you have ongoing for you in the markets, strong clinical stage presence that you have and in commercial as well. So, maybe, but let me kick off on the 2026 guide. You framed it as, 9 to 13% organic growth rate, and then you pointed out the 500 bits of performance framework relative to the bioprocessing and market.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot